Holen Sie sich die Stockscreener-App
223.95
1.24%
2.75
Handel nachbörslich:
223.00
-0.95
-0.42%
Schlusskurs vom Vortag:
$221.20
Offen:
$219
24-Stunden-Volumen:
1.40M
Relative Volume:
0.89
Marktkapitalisierung:
$29.97B
Einnahmen:
$4.29B
Nettoeinkommen (Verlust:
$577.22M
KGV:
53.21
EPS:
4.2086
Netto-Cashflow:
$641.34M
1W Leistung:
-2.09%
1M Leistung:
-25.04%
6M Leistung:
-27.40%
1J Leistung:
-47.91%
1-Tages-Spanne:
$219.00
$224.66
1-Wochen-Bereich:
$210.49
$234.00
52-Wochen-Spanne:
$197.81
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
223.95 | 29.60B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
525.73 | 134.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.99 | 82.06B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.00 | 54.10B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.26 | 44.06B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.05 | 40.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - WBOC TV
Is Alnylam’s Mixed 2026 Guidance Reset Altering The Investment Case For Alny (ALNY)? - simplywall.st
Handelsbanken Fonder AB Sells 29,207 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Drugs that missed the mark in pharma’s last earnings round - Pharma Voice
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Exploring a 71% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
PensionDanmark Pensionsforsikringsaktieselskab Sells 12,119 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Pacer Advisors Inc. Sells 5,110 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assenagon Asset Management S.A. Has $46.87 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (ALNY) Stock forecasts - Yahoo Finance UK
Research Analysts Offer Predictions for ALNY Q3 Earnings - MarketBeat
ALNYLAM PHARMACEUTICALS INC (1ALNY.MI) stock price, news, quote and history - Yahoo Finance Singapore
Empowered Funds LLC Lowers Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) On Lowered TTR Guidance And What It Means For Valuation - simplywall.st
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options - Yahoo Finance
ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Securities Fraud Investigation into Alnylam - GlobeNewswire
Alnylam (ALNY) Turns Profitable as Revenue Mix Shifts: What Changes in Its Investment Story? - simplywall.st
Quantinno Capital Management LP Purchases 8,258 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Securities Fraud Investigation Into Alnylam - GlobeNewswire
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Business Wire
Barclays Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $450.00 - MarketBeat
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: 87.96% Potential Upside Beckons Investors - DirectorsTalk Interviews
ALNYLAM PHARMACEUTICALS INC : RAYMOND JAMES CUTS TARGET PRICE TO $420 FROM $468 - webull.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth at a Reasonable Valuation - ChartMill
Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Wells Fargo & Company Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Forecasts - Yahoo Finance
Alnylam Pharmaceuticals Inc (ALNY) (Q2 2026) Earnings Call Highl - GuruFocus
Alnylam: Q2 Earnings Snapshot - 10tv.com
Alnylam Pharmaceuticals stock hits 52-week low at $226.04 - Investing.com
Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Reduced by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Unlocking Q2 Potential of Alnylam (ALNY): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Why Alnylam’s Best Quarter Ever Didn’t Come With a Richer Valuation - Yahoo Finance
Did Alnylam’s Alzheimer’s Pipeline Advances Just Shift Alnylam Pharmaceuticals' (ALNY) Investment Narrative? - simplywall.st
Alnylam Rises as Investors Weigh Pipeline Momentum, Earnings Setup, and ATTR-CM Positioning - Quiver Quantitative
Alnylam Pharmaceuticals Inc (ALNY) Institutional Confidence - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alnylam Pharmaceuticals (ALNY) Could Be 38% Undervalued After Mivelsiran Trial Progress - simplywall.st
BR:A1LN34 Stock Latest News - TipRanks
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alnylam Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history - Yahoo Finance Australia
ALNY Stock Price TodayAlnylam Pharmaceuticals Inc News, Charts, Retail Sentiment - Stocktwits
Alnylam stock trades steady as RNAi pipeline advances and cash position supports development - Ad-hoc-news.de
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
ALNY Maintains Overweight by JP Morgan -- Price Target Lowered t - GuruFocus
Alnylam Pharmaceuticals Price Target Cut to $400.00/Share From $420.00 by JP Morgan - Moomoo
ALNY|Alnylam Pharmaceuticals Inc|Price:269.400|Chg%:+0.660 - TradingKey
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
2.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):